Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics
Rhea-AI Summary
Renovaro Inc. (NASDAQ:RENB) announced its corporate rebranding to Lunai Bioworks, Inc., reflecting its strategic focus on AI-powered biodefense, drug discovery, and advanced diagnostics. The company's transformation follows its merger with BioSymetrics, which brought established partnerships with major pharmaceutical companies including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
The company's enhanced platform leverages multimodal AI for real-time biological signal analysis, combining early detection, patient stratification, and therapeutic targeting. The stock will continue trading under the ticker symbol RENB on Nasdaq until further notice.
Positive
- Strategic partnerships with major pharmaceutical companies validate their proprietary platforms
- Enhanced diagnostic capabilities using multimodal AI for real-time biological signal analysis
- Integrated platform combining early detection, patient stratification, and therapeutic targeting
- Expanded capabilities in translational analytics, in vivo modeling, and machine vision
Negative
- Rebranding may cause temporary market confusion and recognition challenges
- Integration of merged entities could present operational challenges
News Market Reaction – RENB
On the day this news was published, RENB gained 12.03%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.2% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $61M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered biodefense, drug discovery and advanced diagnostics. The new name underscores the Company's commitment to harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities.
Building on a strong North American base, the Company is enhancing collaboration across its research, development, and commercialization teams and aligning resources to support rapid growth. This strategic integration is designed to improve efficiency, accelerate innovation, and position the Company for long-term success in high-impact biomedical markets worldwide.
As part of its recent merger with BioSymetrics, Lunai Bioworks inherits a robust ecosystem of real-world collaborations with leading biopharmaceutical companies, including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. These partnerships have validated the Company's proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Lunai's diagnostic capabilities now extend beyond traditional boundaries, leveraging multimodal AI to decode complex biological signals in real time. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These innovations are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data.
"Our new name, Lunai Bioworks, captures the fusion of intelligence, innovation, and mission that drives us forward," said David Weinstein, CEO of the Company. "By uniting our teams and focusing squarely on AI-driven biodefense and drug discovery, we are building a platform that can deliver breakthrough solutions for some of the world's most pressing health and security challenges."
The name change was approved by the Board of Directors, and the Company's common stock will continue to trade on Nasdaq under its current ticker symbol, RENB, until further notice.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. More information is available in the Company's filings with the SEC.
Contact:
David Weinstein
Chief Executive Officer
investors@renovaro.com
www.renovarogroup.com
SOURCE: Renovaro Biosciences
View the original press release on ACCESS Newswire
FAQ
Why is Renovaro (NASDAQ:RENB) changing its name to Lunai Bioworks?
Will Renovaro's stock symbol RENB change after becoming Lunai Bioworks?
What major pharmaceutical companies are partnered with Lunai Bioworks (NASDAQ:RENB)?
What are the main focus areas of Lunai Bioworks' AI technology?
Who is the CEO of Lunai Bioworks (formerly Renovaro)?
